Physician
Marilyn S. Norton M.D., INC.
Marilyn S. Norton M.D., INC. was paid $10.31M by Medicaid between Jan 2018 and Dec 2024, across 37 billing codes. Its largest line is J1439, Injection, ferric carboxymaltose, 1 mg — 24% of everything it billed.
33Billing provider infoMARILYN S. NORTON M.D., INC.
CHULA VISTA, CA 91911
CHULA VISTA, CA 91911
33aNPI1326124819assigned 10/27/2006
33bProvider typeHematology & Oncology Physician
28Total paid$10.31M
24GClaims128,187
24DCodes billed37
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in California
Rank by total paid#1 of 180
Median peer was paid$26K
This provider vs. median401×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,354 | $1.34M | |
| 2019 | 18,746 | $1.69M | |
| 2020 | 18,117 | $1.45M | |
| 2021 | 21,405 | $1.82M | |
| 2022 | 22,728 | $1.92M | |
| 2023 | 22,130 | $1.40M | |
| 2024incomplete | 10,707 | $696K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J1439 | Injection, ferric carboxymaltose, 1 mg | 24% | 2,989 | 1,949 | $2.45M |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 14% | 2,143 | 1,698 | $1.42M |
| J0897 | Injection, denosumab, 1 mg | 13% | 802 | 775 | $1.33M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 10.0% | 23,933 | 22,149 | $1.03M |
| J2505 | Injection, pegfilgrastim, 6 mg | 7.7% | 186 | 135 | $788K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 4.9% | 7,639 | 4,886 | $502K |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 4.4% | 115 | 71 | $458K |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 2.6% | 82 | 59 | $265K |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 2.4% | 178 | 81 | $245K |
| J1453 | Injection, fosaprepitant, 1 mg | 2.3% | 1,357 | 959 | $237K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 39,178 | 31,149 | $185K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 9,402 | 7,594 | $168K |
25 more codes
| 99233 | Hospital visit by a doctor, follow-up day (complex) | 1.5% | 4,613 | $156K |
| 99205 | Prolong outpt/office vis | 1.5% | 1,876 | $155K |
| J9271 | Injection, pembrolizumab, 1 mg | 1.3% | 14 | $135K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 2,875 | $133K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 3,393 | $125K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,108 | $100K |
| 96417 | <1% | 2,026 | $84K | |
| 96367 | <1% | 1,835 | $64K | |
| 96415 | <1% | 1,778 | $59K | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 3,295 | $48K |
| 99245 | <1% | 326 | $33K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 364 | $23K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 404 | $22K |
| J9171 | Injection, docetaxel, 1 mg | <1% | 17 | $18K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 217 | $14K |
| 96402 | <1% | 1,067 | $12K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,992 | $10K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 3,145 | $10K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 33 | $6K |
| 96411 | <1% | 395 | $6K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 250 | $5K |
| 99223 | Prolong inpt eval add15 m | <1% | 25 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 19 | $465.51 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 32 | $458.33 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 84 | $316.84 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNORTON, MARILYN (MD./PRESIDENT)